ESAB Debuts its First Battery-Powered Welding Machine
18.11.2022 23:35:00 EET | Business Wire | Press release
Today ESAB, part of ESAB Corporation (NYSE: ESAB), and a world leader in welding and cutting equipment and consumables, unveiled the industry-changing Renegade VOLT™ ES 200i Stick/TIG battery-powered welding system as it closed out SparkWeek, the brand’s week-long, virtual launch event highlighting new welding and fabrication products, automation and robotics solutions, and industry-shaping PPE.
Developed in conjunction with Stanley Black & Decker and powered by four DEWALT® FLEXVOLT® 12 Ah (amp-hour) batteries, the Renegade VOLT marks a crossroads for the welding industry, as ESAB establishes a new product category. For the first-time welders have a battery-powered welding machine which operates on interchangeable, rechargeable power tool batteries. The VOLT is a highly portable option for off-the-grid welding across key industries like maintenance and repair, construction, shipyard, rail, power generation, offshore and farm/agriculture. The product will be available for purchase in Q1 2023.
"ESAB has continuously brought new ideas to the market since the invention of the first coated welding electrode more than a century ago. With the Renegade VOLT, we have taken the idea of portability and supercharged it,” said Olivier Biebuyck, President, EMEA and Global Products, ESAB Corporation. “Up until now, welding jobs have only gone as far as the equipment could reach. Welders were stuck lugging around heavy leads, tripping over cables, and wondering what kind of power would be at the job site. Sometimes welders even spent more time on job set up and breakdown than welding. Today, ESAB eliminated those constraints and ushered in a new age. This is the age of true welding freedom. No cords and heavy leads, no time-consuming setup, no engines, or fuel."
The VOLT launch capped off a string of new and re-imagined solutions from ESAB which were unveiled during SparkWeek. The company made more than 15 announcements between Monday, November 14 and Friday, November 18 via dynamic, live video premieres at ESAB.com/SparkWeek. The event page now features information about these new products and partnerships, including key specifications and availability information:
- Ruffian 150, ESAB’s all-new engine-driven welder
- Rogue EM and Rogue EMP, MIG and multi-process machines
- Rustler, a completely new ESAB line of compact MIG machines
- Renegade 1 Ph DC, powerful-yet-lightweight machine now in single-phase power
- Warrior EDGE CX System with RobustFeed Edge CX and Exeor torch, a next-generation pulse-MIG power source, feeder, and torch product family
- Sentinel A60, the next iteration of ESAB’s industry-leading automatic welding helmet
- Swarm A10, A20, and A30, affordable, performance driven welding helmet portfolio
- Vision T6, easy-to-use CNC cutting machine controller
- Marathon Pac Ultra, a new 1,100-lb. bulk welding wire drum package
- Cutmaster 30+, next-generation manual plasma cutter focused on power and portability
- Thermal Dynamics Automation UC Series, a high precision mechanized plasma system
- Victor Edge 2.0 Phase IV and HRF2400, gas regulator and a regulator/flowmeter combination
- Versotrac Cadet, a compact, efficient, and easy to use submerged arc welding (SAW) tractor
- InduSuite, advanced software that connects welding and cutting data, machinery, and processes across one platform
- PURUS, new and improved premium wire specially formulated to reduce post-weld cleaning
ESAB products are available globally for purchase through select distributors and retail locations. Visit ESAB.com to find a local distributor and learn more about the product portfolio.
About ESAB
ESAB is a world leader in fabrication technology. For more than 100 years ESAB has transformed industries built by fabricators, providing complete workflow solutions through our diverse portfolio of products from more than 40 of the most trusted brands in welding and cutting in the world. From industrial demands to repair and maintenance, innovators that shape the world, rely on ESAB’s portfolio. To learn more, visit ESAB.com.
About ESAB Corporation
ESAB Corporation (NYSE: ESAB) is a world leader in fabrication and gas control technology, providing our partners with advanced equipment, consumables, gas control equipment, robotics, and digital solutions which enable the everyday and extraordinary work that shapes our world. To learn more, visit ESABcorporation.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20221118005574/en/
Contact information
Media Contact for ESAB
Tilea Coleman
Vice President, Corporate Communications
E-mail: mediarelations@esab.com
Phone: 1-301-323-9092
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
2PointZero Group Signals Global Scale With Revenue Surge to AED 21.9 Billion and Net Profit of AED 7.7 Billion in H1 202631.7.2026 14:42:00 EEST | Press release
2PointZero Group (ADX: 2POINTZERO), a leading Abu Dhabi-based investment holding firm, announced its financial results for the first half of 2026, reporting revenue of AED 21.9 billion and delivering a Group Net Profit of AED 7.7 billion. This robust performance is reflected in the Group’s adjusted EBITDA, which reached AED 5.0 billion after excluding fair value changes and one-offs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260731538982/en/ Samia Bouazza, CEO of 2PointZero (Photo: AETOSWire) Net profit from the Group’s businesses increased by 2,301% year-on-year (YoY), driven by the consolidation of Tendam and the mega-merger to form 2PointZero Group, and growth was also supported by new investments in African financial services, entry into the European packaging markets, and steady operational progress across all verticals, bringing the total reported net profit to AED 7.7 billion. Through continued operational integr
Datroway ® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 09:30:00 EEST | Press release
Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on results from the TROPION-Breast02phase 3 trial, which were presented at the 2025 European Society for Medical Oncology Congress and subsequently published in Annals of Oncology. In TROPION-Breast02, which included patients with metastatic TNBC who experienced early relapse following prior treatment, Datroway demonstrated a statis
Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 09:30:00 EEST | Press release
Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said
Half-Year Report on SES’s Liquidity Contract31.7.2026 08:30:00 EEST | Press release
Pursuant to the liquidity contract entered into by SES with BNP Paribas as of 7 April 2026, please see the below update on the progress of the liquidity services. When the liquidity services were implemented as of 7 April 2026, the following assets were in the liquidity account: € 2,500,000 As of 30 June 2026, the following assets appeared on the liquidity account: 228,186 shares; € 816,880. Over the period from 7 April 2026 to 30 June 2026, the following transactions were executed: 1,082 buy transactions; 1,308 sales transactions. Over this same period, the volumes traded represented: 1,093,335 shares and € 8,485,986 on the buy side; 873,399 shares and € 6,860,843 on the sell side. Follow us on: LinkedIn | Facebook | YouTube | X | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where th
SES: Disclosure of Share Buyback Transactions31.7.2026 08:30:00 EEST | Press release
In the time period from June 2, 2026 until and including June 23, 2026, a number of 213,167 shares were bought back within the framework of the share buyback of SES to meet obligations under SES’s Equity Based Compensation Plan (EBCP). Shares were bought back as follows: Day of purchase Aggregated volume in shares Daily weighted average acquisition price of shares (EUR) Market June 2, 2026 27,097 8.8727 DXE June 2, 2026 72,903 8.8556 ENX June 5, 2026 16,624 8.3723 DXE June 5, 2026 31,510 8.4266 ENX June 15, 2026 26,451 7.8423 XPAR June 17, 2026 26,812 7.3910 XPAR June 23, 2026 11,770 7.2200 XPAR The transactions in a detailed form are published on SES’s website: https://www.ses.com/investors/shareholder-information/share-buy-backs. Follow us on: Twitter | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, busin
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom